2018
DOI: 10.1002/anie.201707875
|View full text |Cite
|
Sign up to set email alerts
|

The Cysteinome of Protein Kinases as a Target in Drug Development

Abstract: Drugs that function through covalent bond formation represent a considerable fraction of our repository of effective medicines but safety concerns and the complexity of developing covalent inhibitors has rendered covalent targeting a less attractive strategy for rational drug design. The recent approval of four covalent kinase inhibitors and the development of highly potent covalent kinase probes with exceptional selectivity has raised significant interest in industry and academic research and validated the co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

6
240
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
7
1
1

Relationship

3
6

Authors

Journals

citations
Cited by 197 publications
(257 citation statements)
references
References 110 publications
6
240
0
Order By: Relevance
“…[3] This interest has led to the recent clinical approval of several covalent kinase inhibitors. [4] Especially in the field of antibiotics,covalent inhibitors are prevalent as exemplified by b-lactams, [3] fosfomycin, [5] showdomycin, [6] and optimized arylomycins. [7] Recently,m ethods have emerged to globally identify the exact interaction site of covalent inhibitors in ac ompetitive fashion.…”
Section: Introductionmentioning
confidence: 99%
“…[3] This interest has led to the recent clinical approval of several covalent kinase inhibitors. [4] Especially in the field of antibiotics,covalent inhibitors are prevalent as exemplified by b-lactams, [3] fosfomycin, [5] showdomycin, [6] and optimized arylomycins. [7] Recently,m ethods have emerged to globally identify the exact interaction site of covalent inhibitors in ac ompetitive fashion.…”
Section: Introductionmentioning
confidence: 99%
“…[6] In addition to protein conformational changes,t he rearrangement of water molecules has been discussed as apotential mechanism influencing inhibitor residence time. [10] However, the design of reversibly formed covalent interactions requires the presence of cysteine residues in the drug binding site.M any drug receptors,i ncluding al arge number of kinases,c ontain cysteines in close proximity to their active sites, [11] but the development of covalent inhibitors may not be feasible for all drug targets. [8] In some cases,t he presence of water-shielded hydrogen bonds can also lead to slow dissociation.…”
mentioning
confidence: 99%
“…[9] In addition, reversible covalent inhibitors provide an interesting strategy for prolonging target engagement by transient covalent-bond formation. [10] However, the design of reversibly formed covalent interactions requires the presence of cysteine residues in the drug binding site.M any drug receptors,i ncluding al arge number of kinases,c ontain cysteines in close proximity to their active sites, [11] but the development of covalent inhibitors may not be feasible for all drug targets.…”
mentioning
confidence: 99%
“…In order to conduct a head-to-head comparison of the performance of the azobenzene (AZO) and dialkoxydiphenylsilane (DADPS) chemically-cleavable linkers in characterizing the cellular cysteinome ( Figure 1B), we utilized the cysteine residue-reactive probe iodoacetamide alkyne (IAAyne) as it has been successfully deployed in chemical proteomic applications 11,19 , and serves as a tool to profile cysteine-reactive covalent drugs used for disease indications 29 . We initiated our studies by subjecting 1 mg of lysate derived from K562 chronic myelogenous leukemia cells to alkylation in the presence of IAAyne (100 µM).…”
Section: Resultsmentioning
confidence: 99%